In the last trading session, 1.01 million shares of the Rani Therapeutics Holdings Inc (NASDAQ:RANI) were traded, and its beta was 0.15. Most recently the company’s share price was $1.42, and it changed around -$0.1 or -6.58% from the last close, which brings the market valuation of the company to $81.55M. RANI currently trades at a discount to its 52-week high of $8.75, offering almost -516.2% off that amount. The share price’s 52-week low was $1.24, which indicates that the current value has risen by an impressive 12.68% since then. We note from Rani Therapeutics Holdings Inc’s average daily trading volume that its 10-day average is 3.71 million shares, with the 3-month average coming to 1.02 million.
Rani Therapeutics Holdings Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended RANI as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Rani Therapeutics Holdings Inc is expected to report earnings per share of -0.24 for the current quarter.
Rani Therapeutics Holdings Inc (NASDAQ:RANI) trade information
Instantly RANI has showed a red trend with a performance of -6.58% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.8200 on recent trading dayincreased the stock’s daily price by 21.98%. The company’s shares are currently up 3.65% year-to-date, but still up 4.41% over the last five days. On the other hand, Rani Therapeutics Holdings Inc (NASDAQ:RANI) is 4.41% up in the 30-day period. We can see from the shorts that 1.49 million shares have been sold at a short interest cover period of 0.36 day(s).
The consensus price target as assigned by Wall Street analysts is $10, which translates to bulls needing to increase their stock price by 85.8% from its current value. Analyst projections state that RANI is forecast to be at a low of $9 and a high of $28.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 0.28%. Rani Therapeutics Holdings Inc earnings are expected to increase by 7.86% in 2025, but the outlook is positive 18.19% per year for the next five years.
RANI Dividends
Rani Therapeutics Holdings Inc’s next quarterly earnings report is expected to be released in March.
Rani Therapeutics Holdings Inc (NASDAQ:RANI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 30.61% of Rani Therapeutics Holdings Inc shares, and 19.59% of them are in the hands of institutional investors. The stock currently has a share float of 28.23%. Rani Therapeutics Holdings Inc stock is held by 34.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 2.7265% of the shares, which is about 0.71 million shares worth $2.7 million.
NAN FUNG GROUP HOLDINGS LTD, with 1.8959% or 0.49 million shares worth $1.88 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 518.7 shares worth $0.74 million, making up 1.56% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 172.98 shares worth around $0.25 million, which represents about 0.52% of the total shares outstanding.
